炎症性腸疾患の日本人の子供の成長障害:多センター前向きなコホート研究
Hirotaka Shimizu1, Ryusuke Nambu2, Nao Tachibana3
1Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Journal of pediatric gastroenterology and nutrition
|August 28, 2025
まとめ
成長障害 (GI) は,炎症性腸疾患 (IBD) の子供,特に若い潰瘍性大腸炎 (UC) の患者に影響します. 早期にステロイドを節約する治療と 調整されたモニタリングは,小児IBDのより良い結果の鍵です.
科学分野:
- 小児胃腸内科
- 炎症性腸疾患の研究
- 成長と発展に関する研究
背景:
- 成長障害 (GI) は小児炎症性腸疾患 (IBD) の重要な懸念事項である.
- 潰瘍性大腸炎 (UC) とクローン病 (CD) の特異的な特徴と罹患率を理解することは,効果的な管理に不可欠です.
- 早期発見と介入は 罹患児の長期的な健康改善に不可欠です
研究 の 目的:
- IBDと診断された子供の成長障害 (GI) の流行と特異性を調査する.
- UCとCDの子供の成長パターンと回復率を比較する.
- 乳幼児のIBD集団内の危険因子と脆弱なサブグループを特定する.
主な方法:
- 日本の小児IBDレジストリ (2012-2020) からUC (n=257) とCD (n=145) を含む402人の子どもを対象とした前向きな観察研究.
- 成長障害 (GI) はパリの分類基準を用いて定義された.
- 少なくとも2年間の追跡期間で307人の子どもを対象に長期的アウトカムを評価した.
主要な成果:
- 診断時に,UC (6. 2%) とCD (8. 3%) の間では,GIの罹患率は類似していた.
- 0~4歳でUCと診断された子供は, GI率 (35. 3%) が著しく高かった.
- 2年後の成長回復は,初期GI患者ではCD患者 (50%) と比較してUC患者より低かった. 新発症性GIはUCの23%とCDの16%で,持続性GIはUCの16%とCDの11%で報告された. 長期にわたるコルチコステロイドの使用は,UCにおける持続的なGIに関連していた.
結論:
- IBDの日本人の子供では 独特の成長パターンが観察され,若いUC患者は特に脆弱である.
- 小腸の病変はCDの GI と関連しており,小腸の徹底的な評価の必要性を強調しています.
- 幼児のIBDの長期的改善には,年齢特有の患者中心の成長監視と早期のステロイドを節約する戦略が不可欠です.
関連する概念動画
Inflammatory Bowel Disease II: Crohn's Disease
375
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
375
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
413
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
413
Inflammatory Bowel Disease I: Ulcerative Colitis
316
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
316
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
Inflammatory Bowel Disease V: Surgical Management
206
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
206
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264


